Improved compliance and patient satisfaction with estradiol vaginal tablets in postmenopausal women previously treated with another local estrogen therapy

Figures & data

Table 1 Demographic information for survey respondents

Patient characteristics, n (%)	n = 79
Age, years
35–57	41 (52)
≥58	38 (48)
Ethnic background
White	72 (91)
Black	3 (4)
Hispanic	1 (1)
Asian	0
Declined to answer	3 (4)
Sexual status
Active	52 (66)
Inactive	18 (23)
Declined to answer	9 (11)
Current regimen
Vaginal tablets	61 (77)
Vaginal tablets and OTC lubricant or moisturizer	18 (23)
Prior regimen
Cream user	67 (85)
Ring user	7 (9)
Cream and ring user	5 (6)

Abbreviation: OTC, over the counter.

Figure 1 Symptoms of vaginal atrophy considered bothersome by patients, according to age group.

Notes: *Vaginal itchiness: older versus younger (P = 0.0345). **Vaginal soreness: older versus younger (P = 0.0492).

Abbreviation: UTIs, urinary tract infections.

Figure 2 Reasons for switching from vaginal cream to vaginal tablet.

Figure 3 User-friendliness ratings of the different local estrogen therapy formulations.

Figure 4 Positive attributes of vaginal estradiol tablets.